Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity.
Cerise Yuen-Ki ChanVincent Wai-Hin YuenDavid Kung-Chun ChiuChi-Ching GohKelsie L ThuDavid W CesconIsabel Soria-BretonesCheuk-Ting LawJacinth Wing-Sum CheuDerek LeeAki Pui-Wah TseKel Vin TanMisty Shuo ZhangBowie Po-Yee WongChun Ming WongPek-Lan KhongIrene Oi Lin NgMark R BrayTak Wah MakThomas Chung-Cheung YauCarmen Chak-Lui WongPublished in: Hepatology (Baltimore, Md.) (2022)
We show that by targeting a centrosome regulator, PLK4, to activate the cytosolic DNA sensing-mediated immune response, CFI-400945 effectively restrained tumor progression through cell cycle inhibition and inducing antitumor immunity to achieve a durable suppressive effect even in late-stage mouse HCC.